Sustained mitogen-activated protein kinase activation is induced by transforming erbB receptor complexes

DNA and Cell Biology

Volumn 18, Issue 10, 1999, Pages 731-741

  Wu, Chuan Jin ^a,d   Qian, Xiaolan ^e   O'Rourke, Donald M ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; FIBROBLAST; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; BRAIN NEOPLASMS; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, NEOPLASTIC; DIMERIZATION; DNA DAMAGE; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; FIBROBLASTS; GENES, ERBB; GLIOBLASTOMA; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN HYBRIDIZATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; SEQUENCE DELETION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032699144     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/104454999314872     Document Type: Article

References (72)

1. ALTIOK, N., ALTIOK, S., and CHANGEUX, J.P. (1997). Heregulin-stimulated acetylcholine receptor gene expression in muscle: Requirement for MAP kinase and evidence for a parallel inhibitory pathway independent of electrical activity. EMBO J. 16, 717-725.
2. AMUNDADOTTIR, L.T., and LEDER, P. (1998). Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene 16, 737-746.
3. ANTONYAK, M.A., MOSCATELLO, D.K., and WONG, A.J. (1998). Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J. Biol. Chem. 273, 2817-2822.
4. BONFINI, L., MIGLIACCIO, E., PELICCI, G., LANFRANCONE, L., and PELICCI, P.G. (1996). Not all Shc's roads lead to Ras. Trends Biochem. Sci. 21, 257-261.
5. CARTER, S., AUER, K.L., REARDON, D.B., BIRRER, M., FISHER, P.B., VALERIE, K., SCHMIDT-ULLRICH, R., MIKKELSON, R., and DENT, P. (1998). Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells. Oncogene 16, 2787-2796.
6. COWLEY, S., PATERSON, H., KEMP, P., and MARSHALL, C.J. (1994). Activation of MAP kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77, 841-852.
7. DAUB, H., WEISS, F.U., WALLASCH, C., and ULLRICH, A. (1996). Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379, 557-560.
8. DEB, T.B., WONG, L., SALOMON, D.S., ZHOU, G., DIXON, J.E., GUTKIND, J.S., THOMPSON, S.A., and JOHNSON, G.R. (1998). A common requirement for the catalytic activity and both SH2 domains of SHP-2 in mitogen-activated protein (MAP) kinase activation by the ErbB family of receptors: A specific role for SHP-2 in MAP, but not c-Jun amino-terminal kinase activation. J. Biol. Chem. 273, 16643-16646.
9. DOWNWARD, J. (1994). The Grb2/Sem-5 adaptor protein. FEBS Lett 338, 113-117.
10. DREBIN, J.A., LINK, V.C., STERN, D.F., WEINBERG, R.A., and GREENE, M.I. (1985). Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41, 695-706.
11. FELDKAMP, M.M., ANGELOV, L., and GUHA, A. (1999). Neurofibromatosis type 1 peripheral nerve tumors: Aberrant activation of the Ras pathway. Surg. Neurol. 51, 211-218.
12. GALBIATI, F., VOLONTE, D., ENGELMAN, J.A., WATANABE, G., BURK, R., PESTELL, R.G., and LISANTI, M.P. (1998). Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J. 17, 6633-6648.
13. GUHA, A., FELDKAMP, M.M., LAU, N., BOSS, G., and PAWSON, A. (1997). Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 15, 2755-2765.
14. GUTMANN, D.H., GIORDANO, M.J., MAHADEO, D.K., LAU, N., SILBERGELD, D., and GUHA, A. (1996). Increased neurofibromatosis 1 gene expression in astrocytic tumors: Positive regulation by p21-ras. Oncogene 12, 2121-2127.
15. HUANG, H.S., NAGANE, M., KLINGBEIL, C.K., LIN, H., NISHIKAWA, R., JI, X.D., HUANG, C.M., GILL, G.N., WILEY H.S., and CAVENEE, W.K. (1997). The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J. Biol. Chem. 272, 2927-2935.
16. ICHIJO, H., NISHIDA, E., IRIE, K., TEN DIJKE, P., SAITOH, M., MORIGUCHI, T., TAKAGI, M., MATSUMOTO, K., MIYAZONO, K., and GOTOH, Y. (1997). Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275, 90-94.
17. IMPEY, S., OBRIETAN, K., and STORM, D.R. (1999). Making new connections: Role of ERK/MAP kinase signaling in neuronal plasticity. Neuron 23, 11-14.
18. JONESON, T., WHITE, M.A., WIGLER, M.H., and BAR-SAGI, D. (1996). Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of RAS. Science 271, 810-812.
19. KHARITONENKOV, A., CHEN, Z., SURES, I., WANG, H., SCHILLING, J., and ULLRICH, A. (1997). A family of proteins that inhibit signalling through tyrosine kinase receptors. Nature 386, 181-186.
20. KHOSRAVI-FAR, R., WHITE, M.A., WESTWICK, J.K., SOLSKI, P.A., CHRZANOWSKA-WODNICKA, M., VAN AELST, L., WIGLER, M. H., and DER, C.J. (1996). Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol. Cell. Biol. 16, 3923-3933.
21. KLESSE, L.J., MEYERS, K.A., MARSHALL, C.J., and PARADA, L.F. (1999). Nerve growth factor induces survival and differentiation through two distinct signaling cascades in PC12 cells. Oncogene 18, 2055-2068.
22. KOKAI, Y., MYERS, J.N., WADA, T., BROWN, V.I., LeVEA, C.M., DAVIS, J.G., DOBASHI, K., and GREENE, M.I. (1989). Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58, 287-292.
23. LOUIS, D.N. (1997). A molecular genetic model of astrocytoma histopathology. Brain Pathol. 7, 755-764.
24. MANSOUR, S.J., MATTEN, W.T., HERMANN, A.S., CANDIA, J.M., RONG, S., FUKASAWA, K., VANDE WOUDE, G.F., and AHN, N.G. (1994). Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265, 966-970.
25. MARSHALL, C.J. (1994). MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr. Opin. Genet. Dev. 4, 82-89.
26. MARSHALL, C.J. (1995). Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell 80, 179-185.
27. MARSHALL, C.J. (1998). Taking the Rap. Nature 392, 553-554.
28. MELOCHE, S. (1995). Cell cycle reentry of mammalian fibroblasts is accompanied by the sustained activation pp44mapk and p42mapk isoforms in the G1 phase and their inactivation at the G1/S transition. J. Cell. Physiol. 163, 577-588.
29. MELOCHE, S., SEUWEN, K., PAGES, G., and POUYSSEGUR, J. (1992). Biphasic and synergistic activation of p44mapk (ERK1) by growth factors: Correlation between late phase activation and mitogenicity. Mol. Endocrinol. 6, 845-854.
30. MIGLIACCIO, E., MELE, S., SALCINI, A.E., PELICCI, G., LAI, K.M., SUPERTI-FURGA, G., PAWSON, T., Di FORE, P.P., LANFRANCONE, L., and PELICCI, P.G. (1997). Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptorMAP kinase-fos signalling pathway. EMBO J. 16, 706-716.
31. MONTGOMERY, R.B., MOSCATELLO, D.K., WONG, A.J., COOPER, J.A., and STAHL, W.L. (1995). Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor. J. Biol. Chem. 270, 30562-30566.
32. MOSCATELLO, D.K., MONTGOMERY, R.B., SUNDARESHAN, P., McDANEL, H., WONG, M.Y., and WONG, A.J. (1996). Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 13, 85-96.
33. NAGANE, M., LEVITZKI, A., GAZIT, A., CAVENEE, W.K., and HUANG, H.-J.S. (1998). Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc. Natl. Acad. Sci. USA 95, 5724-5729.
34. NEWBOLD, R.F., and OVERELL, R.W. (1983). Fibroblast immortality is a prerequisite for transformation by EJ c-Ha-ras oncogene. Nature 304, 648-651.
35. NISHIKAWA, R., JI, X.D., HARMON, R.C., LAZAR, C.S., GILL, G.N., CAVENEE, W.K., and HUANG, H.J. (1994). A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. USA 91, 7727-7731.
36. NOWAK, F., JACQUEMIN-SABLON, A., and PIERRE, J. (1997). Expression of the activated p185erbB2 tyrosine kinase in human epithelial cells leads to MAP kinase activation but does not confer oncogenicity. Exp. Cell Res. 231, 251-259.
37. O'ROURKE, D.M., NUTE, E.J.L., DAVIS, J.G., WU, C., LEE, A., MURALI, R., ZHANG, H.-T., QIAN, X., KAO, C.-C., and GREENE, M.I. (1998a). Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: Implications for subdomain contributions to receptor assembly. Oncogene 16, 1197-1207.
38. O'ROURKE, D.M., KAO, G.D., SINGH, N., PARK, B.-W., MUSCHEL, R.J., WU, C.-J., and GREENE, M.I. (1998b). Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signalling in human cancer cells. Proc. Natl. Acad. Sci. USA 95, 10842-10847.
39. O'ROURKE, D.M., QIAN, X., ZHANG, H.-T., DAVIS, J.G., NUTE, E., MEINKOTH, J., and GREENE, M.I. (1997a). Trans receptor inhibition of human glioblastoma cells by ErbB family ectodomains. Proc. Natl. Acad. Sci. USA 94, 3250-3255.
40. O'ROURKE, D.M., ZHANG, X., and GREENE, M.I. (1997b). Principles of receptor-based inhibition of ErbB family receptor kinases: Prospects for new therapies for human cancers. Proc. Assoc. Am. Physicians 109, 209-219.
41. OLSON, M.F., ASHWORTH, A., and HALL, A. (1995). An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science 269, 1270-1272.
42. OLSON, M.F., PATERSON, H.F., and MARSHALL, C.J. (1998). Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature 394, 295-299.
43. PAUL, A., WILSON, S., BELHAM, C.M., ROBINSON, C.J., SCOTT, P.H., GOULD, G.W., and PELVIN, R. (1997). Stress-activated protein kinases: Activation, regulation and function. Cell Signal. 9, 403-410.
44. PELICCI, G., LANFRANCONE, L., SALCINI, A.E., ROMANO, A., MELE, S., GRAZIA, B.M., SEGATTO, O., DI, F.P., and PELICCI, P.G. (1995). Constitutive phosphorylation of Shc proteins in human tumors. Oncogene 11, 899-907.
45. PRIGENT, S.A., NAGANE, M., LIN, H., HUVAR, I., BOSS, G.R., FERAMISCO, J.R., CAVENEE, W.K., and HUANG, H.-J.S. (1996). Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J. Biol. Chem. 271, 25639-25645.
46. PRUSS, R.M., and HERSCHMAN, H.R. (1977). Variants of 3T3 cells lacking mitogenic response to epidermal growth factor. Proc. Natl. Acad. Sci. USA 74, 3918-21.
47. QIAN, X., DOUGALL, W.C., HELLMAN, M.E., and GREENE, M.I. (1994). Kinase-deficient neu proteins suppress epidermal growth receptor function and abolish cell transformation. Oncogene 9, 1507-1514.
48. QIAN, X., O'ROURKE, D.M., FEI, Z., KAO, C.-C., ZHANG, H.-T., and GREENE, M.I. (1999). Domain-specific interactions between the p185neu and EGF receptor kinases determine differential signalling outcomes. J. Biol. Chem. 274, 574-583.
49. neu kinase activity and cellular transformation by co-expression of a truncated Neu protein. Oncogene 13, 2149-2157.
50. QIU, R.G., CHEN, J., KIRN, D., McCORMICK, F., and SYMONS, M. (1995). An essential role for Rac in Ras transformation. Nature 374, 457-459.
51. ROBINSON, M.I., and COBB, M.H. (1997). Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 9, 180-186.
52. ROBINSON, M.J., STIPPEC, S.A., GOLDSMITH, E., WHITE, M.A., and COBB, M.H. (1998). A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neunte outgrowth and cell transformation. Curr. Biol. 8, 1141-1150.
53. RODRIGUES, G.A., PARK, M., and SCHLESSINGER, J. (1997). Activation of the INK pathway is essential for transformation by the Met oncogene. EMBO J 16, 2634-2645.
54. RODRIGUEZ-VICIANA, P., WARNE, P.H., KHWAJA, A., MARTE, B.M., PAPPIN D., DAS, P., WATERFIELD, M.D., RIDLEY, A., and DOWNWARD, J. (1997). Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89, 457-467.
55. SASAOKA, T., LANGLOIS, W.J., LEITNER, I.W., DRAZNIN, B., and OLEFSKY, J.M. (1994). The signaling pathway coupling epidermal growth factor receptors to activation of p21ras. J. Biol. Chem. 269, 32621-32625.
56. SEPP-LORENZINO, L., MA, Z., RANDS, E., KOHL, N.E., GIBBS, J.B., OLIFF, A. and ROSEN, N. (1995). A peptidomimetic inhibitor of famesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 55, 5302-5309.
57. SERRANO, M., LIN, A.W., MCCURRACH, M.E., BEACH, D., and LOWE, S.W. (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602.
58. SHI, Z.Q., LU, W., and FENG, G.S. (1998). The Shp-2 tyrosine phosphatase has opposite effects in mediating the activation of extracellular signal-regulated and c-Jun NH2-terminal mitogen-activated protein kinases. J. Biol. Chem. 273, 4904-4908.
59. TRAVERSE, S., SEEDORF, K., PATERSON, H., MARSHALL, C.J., COHEN, P., and ULLRICH, A. (1994). EGF triggers neuronal differentiation of PC12 cells that overexpress the EGF receptor. Curr. Biol. 4, 694-701.
60. VAN AELST, L., and D'SOUZA-SCHOREY, C. (1997). Rho GTPases and signaling networks. Genes Dev. 11, 2295-2322.
61. VIEIRA, A.V., LAMAZE, C., and SCHMID, S.L. (1996). Control of EGF receptor signaling by clathrin-mediated endocytosis. Science 274, 2086-2089.
62. WADA, T., QIAN, X.L., and GREENE, M.I. (1990). Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 61, 1339-47.
63. WARY, K.K., MAINIERO, F., ISAKOFF, S.J., MARCANTONIO, E.E., and GIANCOTTI, F.G. (1996). The adaptor protein Shc couples a class of integrins to the control of cell cycle progression. Cell 87, 733-743.
64. WASYLYK, B., HAGMAN, J., and GUTIERREZ-HARTMANN, A. (1998). Ets transcription factors: Nuclear effectors of the Ras-MAP-kinase signaling pathway. Trends Biochem. Sci. 23, 213-216.
65. WATTS, R.G., HUANG, C., YOUNG, M.R., LI, J.J., DONG, Z., PENNIE, W.D., and COLBURN, N.H. (1998). Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation. Oncogene 17, 3493-3498.
66. WEBER, J.D., RABEN, D.M., PHILLIPS, P.J., and BALDASSARE, J.J. (1997). Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. Biochem. J. 326, 61-68.
67. WHITE, M.A., NICOLETTE, C., MINDEN, A., POLVERINO, A., VAN AELST, L., KARIN, M., and WIGLER, M.H. (1995). Multiple Ras functions can contribute to mammalian cell transformation. Cell 80, 533-541.
68. WILLUMSEN, B.M., VASS, W.C., VELU, T.J., PAPAGEORGE, A.C., SCHILLER, J.T., and LOWY, D.R. (1991). The bovine papillomavirus E5 oncogene can cooperate with ras: Identification of p21 amino acids critical for transformation by c-rasH but not v-rasH. Mol. Cell. Biol. 11, 6026-6033.
69. 3 domain of GRB2. J. Biol. Chem. 271, 20981-20984.
70. XIA, Z., DICKENS, M., RAINGEAUD, J., DAVIS, R.J., and GREENBERG, M.E. (1995). Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270, 1326-1331.
71. YORK, R.D., YAO, H., DILLON, T., ELLIG, C.L., ECKERT, S.P., MCCLESKEY, E.W., and STORK, P.J.S. (1998). Rap1 mediates sustained MAP kinase activation induced by nerve growth factor. Nature 392, 622-626.
72. ZHU, X., and ASSOIAN, R.K. (1995). Integrin-dependent activation of MAP kinase: A link to shape-dependent cell proliferation. Mol. Biol. Chem. 6, 273-282.